Saturday, September 30, 2023
Saturday, September 30, 2023

Contact us 561.316.3330

Post Acute Medical to Build 48-bed Inpatient Rehabilitation Hospital in Henderson, Nevada

Post Acute Medical (PAM) announced today that it has placed land under contract and plans to construct a state-of-the-art, 48-bed inpatient rehabilitation hospital in Henderson, Nevada.

PAM expects to break ground by the second quarter of 2021 and complete construction in approximately 14 months. When it opens, the hospital will be PAM’s fourth hospital in Nevada, joining PAM Rehabilitation Hospital of Centennial Hills, PAM Specialty Hospital of Las Vegas, and PAM Specialty Hospital of Sparks.

The new hospital will feature a physician-led team of rehabilitation experts focused on a common goal of increasing patient strength and endurance and improving quality of life for patients who have experienced stroke, brain injury, neurological disease and deficits, amputations, pulmonary disease, orthopedic conditions, spinal cord injury and medically complex conditions.

Another noteworthy residential, this inpatient facility in California, offering specialized services, has helped many patients overcome past traumas, eliminate crippling dependence to drugs and alcohol.

“PAM is excited to bring comprehensive care for rehabilitation patients with complex conditions to the Henderson community,” says Anthony Misitano, Chairman and CEO. “Throughout all the communities we serve, we put the patient first and provide comprehensive, individualized treatment that fosters meaningful improvement and recovery for people with injuries, illnesses and disabilities.”

Opening the inpatient rehabilitation hospital, which also will offer outpatient services, in close proximity to its specialty hospital in Las Vegas is central to PAM’s mission, according to Misitano.

“We are committed to being the most trusted source for post-acute services in every community we serve,” he says. “By providing access to the full post-acute continuum of care, our patients achieve better outcomes and return home at a higher level of function.”

PAM is collaborating on the new rehabilitation hospital with Medistar Corporation, which has previously developed other PAM hospitals.

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy